What is IPH5201?
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
CD39 is an extracellular membrane-bound enzyme that is expressed on both tumor infiltrating immune cells and stromal cells, in several cancer types.
CD39 inhibits the immune system by degrading extracellular adenosine triphosphate (ATP) into adenosine diphosphate (ADP) and adenosine monophosphate (AMP), and AMP is then further degraded into adenosine by CD73. IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway. By promoting the accumulation of immunostimulatory ATP and preventing the production of immunosuppressive adenosine, blocking CD39 can boost anti-tumor activity.
Mechanism of action of IPH5201
The non-small cell lung cancer (NSCLC) is a malignant tumor that develops from the cells lining the walls of the bronchi, bronchi and alveoli. Non-small cell lung cancer accounts for 85-90% of all lung cancers diagnosed each year in France. It has a poor prognosis, with a 5-year survival rate of less than 20% for all stages combined.
| IPH5201 CD39 Co-development with AstraZeneca | MATISSE: perioperative Phase 2 clinical trial in combination with durvalumab (anti-PD-L1) and chemotherapy in patients with early-stage, operable non-small-cell lung cancer
| |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 | |
In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration including an option for co-development and co-commercialization of IPH5201.
The financial terms of the agreement include payments to Innate Pharma of up to $885 million and double-digit royalties on sales. To date, Innate has received $60 million under the IPH5201 agreement with AstraZeneca.
Publications, posters and presentations